| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
AEOL-10150 targets reactive oxygen species (ROS) and reactive nitrogen species (RNS). It acts as a catalytic mimetic of superoxide dismutase (SOD), an enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. By scavenging ROS and RNS, AEOL-10150 protects cells and tissues from oxidative stress-induced damage. It also modulates the NF-κB signaling pathway, which is involved in inflammation. This dual mechanism of action—scavenging free radicals and modulating inflammation—underlies its cytoprotective effects.
|
|---|---|
| ln Vitro |
In vitro, AEOL-10150 has been shown to scavenge a broad range of reactive oxygen species and free radicals. As a catalytic antioxidant, it mimics and amplifies the body's natural enzymatic systems for eliminating these damaging compounds. The compound's ability to modulate NF-κB signaling has been confirmed in cell-based studies. These in vitro studies establish AEOL-10150 as a potent antioxidant and anti-inflammatory agent.
|
| ln Vivo |
In vivo, AEOL-10150 has been investigated for its protective effects in various disease models. It has been shown to protect the lungs from radiation-induced injury. The compound has been studied for its therapeutic potential in acute radiation syndrome, neurodegenerative diseases, pulmonary injury, and inflammatory disorders. By reducing oxidative injury and inflammation, AEOL-10150 offers promise as a cytoprotective agent in preclinical biomedical research.
|
| Enzyme Assay |
In vitro enzyme assays for AEOL-10150 measure its superoxide dismutase (SOD) mimetic activity. The compound is incubated with a superoxide-generating system (e.g., xanthine/xanthine oxidase) and a detector molecule (e.g., cytochrome c or nitroblue tetrazolium). The inhibition of superoxide-mediated reduction of the detector is measured, and the IC50 is determined. The compound's ability to scavenge other ROS, such as hydrogen peroxide and hydroxyl radicals, can also be assessed using specific assays.
|
| Cell Assay |
In vitro cell-based assays for AEOL-10150 are used to study its cytoprotective effects against oxidative stress. Cells are treated with AEOL-10150 and then exposed to oxidative stress inducers, such as hydrogen peroxide or radiation. Cell viability is assessed using assays such as MTT or LDH release. Intracellular ROS levels are measured using fluorescent probes. The compound's effects on NF-κB signaling and inflammatory cytokine production can also be assessed. These assays confirm the compound's antioxidant and anti-inflammatory activity.
|
| Animal Protocol |
In vivo animal experiments for AEOL-10150 have been conducted in models of radiation injury, pulmonary injury, and neurodegenerative diseases. In a typical study, AEOL-10150 is administered to animals, and the protective effects against oxidative stress and inflammation are assessed. Endpoints include tissue damage, inflammatory markers, and survival. The compound has been shown to protect the lungs from radiation-induced injury. These studies provide evidence for the in vivo efficacy of AEOL-10150.
|
| ADME/Pharmacokinetics |
AEOL-10150 pentachloride has a molecular weight of 1033.24 g/mol and a molecular formula of C48H56Cl5MnN12. It has a purity of ≥95%. The compound is a solid. It is soluble in DMSO and other organic solvents. The pentachloride salt form enhances stability and solubility for research applications. For storage, it is recommended to keep the powder at -20°C. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for AEOL-10150 is not provided in standard product descriptions. As a research compound, its toxicity profile has not been extensively characterized. In vivo studies have used AEOL-10150 at doses that are protective against oxidative stress without reported overt toxicity. However, comprehensive toxicological studies have not been reported. As with all research chemicals, standard laboratory safety precautions should be followed when handling AEOL-10150. Its use is limited to research applications.
|
| Additional Infomation |
AEOL-10150 is a research compound and is not approved for any clinical or therapeutic use. It is a synthetic metalloporphyrin compound with potent antioxidant and anti-inflammatory properties. AEOL-10150 functions as a catalytic mimetic of superoxide dismutase (SOD), scavenging reactive oxygen species (ROS) and reactive nitrogen species (RNS). It also modulates the NF-κB signaling pathway. The compound has been investigated for therapeutic potential in conditions such as acute radiation syndrome, neurodegenerative diseases, pulmonary injury, and inflammatory disorders. It is a valuable research tool for studying oxidative stress and inflammation.
|
| Molecular Formula |
C48H56CL5MNN12
|
|---|---|
| Molecular Weight |
1033.2417
|
| CAS # |
286475-30-7
|
| Appearance |
Light brown to black solid powder
|
| Synonyms |
AEOL 10150 AEOL10150 AEOL-10150
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~120.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (4.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.17 mg/mL (4.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9678 mL | 4.8391 mL | 9.6783 mL | |
| 5 mM | 0.1936 mL | 0.9678 mL | 1.9357 mL | |
| 10 mM | 0.0968 mL | 0.4839 mL | 0.9678 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
